Citation:Novartis Pharmaceuticals 2017

Citation

Novartis Pharmaceuticals. Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis). [homepage on the internet] ClinicalTrials.gov; 2017 Nov 7 [cited 2019 Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT03333694.

This is a publication of NCT03333694

Critical appraisals

• Assign a critical appraisal

Cited by

1. 10.3 Topical treatments and photodynamic therapy: health system implications and discussion